AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02417506 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-OA-07 (Lanconone)
Study NCT02417506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Study NCT04052633 — intervention group
Intervention type: RADIATION
Intervention: intraoperative cholangiography
Description: success or failure of cholangiography
Study NCT02696967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLR325
Description: CLR325 Concentrate for solution for infusion
Study NCT02696967 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT02631590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
Study NCT02631590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
Study NCT02631590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
Study NCT02789293 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeOP1 device
Description: Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
Study NCT04688008 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Hetrombopag
Description: Drug: Early phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions~Drug: Late phase hetrombopag olamine formulation single oral dose of 5 mg hetrombopag under fasting conditions
Study NCT03668899 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
Study NCT03668899 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: irrigation
Description: irrigation of root canals during mechanical preparation for pueposes of cleaning and disinfection
Study NCT02351856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-371797, p38 inhibitor, oral
Description: multiple dose, single schedule
Study NCT04685044 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: IH 1Tx32Rx Head Array
Description: BrainPET insert
Study NCT02341677 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SmartTarget - Biopsy
Description: MRI to ultrasound fusion guided prostate biopsy
Study NCT00214890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: 300 mg once daily
Study NCT00214890 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir
Description: 600 mg once daily
Study NCT01450332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee-T-Nol
Description: The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
Study NCT01772316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab
Description: 162 mg subcutaneously weekly or every two weeks, 96 weeks
Study NCT01262196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP4OX
Description: 4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
Study NCT01262196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Normal saline (0.9%) solution
Study NCT03164239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - telephone and print exercise intervention
Description: Intervention has previously been described.
Study NCT03249116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: animal-assisted intervention
Description: Interaction with a therapy dog
Study NCT03249116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active control
Description: Interaction with a stuffed dog
Study NCT01235078 — intervention group
Intervention type: DEVICE
Intervention: EZ-IO
Description: powered intraosseous vascular access system
Study NCT01177397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-223
Description: Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
Study NCT03169725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strain)
Description: Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
Study NCT03169725 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Poliomyelitis Vaccine (Salk strain)
Description: Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
Study NCT01318239 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCE MRI
Description: MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy.
Study NCT01318239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DCE MRI
Description: MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).~MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy.
Study NCT04867304 — intervention group
Intervention type: OTHER
Intervention: Patient education about chronic pancreatitis.
Description: Patients in the second cohort were educated about their disease phenotype in a structured and personalised manner that included their disease course, symptoms, imaging, treatment option and possible long-term outcomes and prognosis. This was followed by answering all the queries of the patient and their caregivers.~The patients were advised to visit the Pancreas clinic after 3-months for re-evaluation of the clinical, psychological and metabolic parameters.
Study NCT00329589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib)
Study NCT01039376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose was 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years.
Study NCT01039376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Observation/Safety Evaluation
Study NCT00563472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol
Description: 10 mg orally per day for 28 days
Study NCT00563472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol
Description: 20 mg orally per day for 28 days
Study NCT00563472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol and desogestrel
Description: 20 mg estetrol and 150 microg desogestrel orally per day for 28 days
Study NCT00563472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estetrol and progesterone
Description: 20 mg estetrol and 200 mg progesterone orally per day for 28 days
Study NCT03252925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: 50mg/Kg.d, oral
Study NCT03252925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 50mg/Kg.d, oral
Study NCT00458978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Description: Given orally
Study NCT00458978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01635426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 75 mg daily for 2 months after meals
Study NCT01635426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg daily for 2 months after meals
Study NCT04268381 — intervention group
Intervention type: OTHER
Intervention: Biochemical analysis
Description: aMMP-8 is measured by immunofluorometric assay (IFMA).
Study NCT00357552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: Once daily
Study NCT00357552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: Twice daily
Study NCT00123422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing retraining
Description: exercise training with computerized training program
Study NCT00123422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heliox
Description: exercise training with a helium oxygen combination
Study NCT00123422 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: exercise training
Study NCT01657019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate
Description: 50 or 70 mg administered orally, once a day for 52 weeks
Study NCT03089281 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CRT-D
Description: Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing. All enrolled subjects with implanted BSC X4 CRT-D system and identified with an RV-LV delay of ≥70ms were 1:1 randomized. Randomization occurred in the electronic data capturing system.
Study NCT00842296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF ablation (ClosureFAST)
Description: Segmental RF Ablation with the CLF catheter
Study NCT00967837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulsatile Intravenous Insulin Therapy
Description: Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
Study NCT02902146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bougie
Study NCT02902146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal tube
Study NCT02795403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw of 150ml, twice
Study NCT02791503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
Study NCT02791503 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic ablative radiotherapy (SABR)
Description: Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
Study NCT02282605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XF-73 nasal gel
Study NCT02282605 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal gel
Study NCT02282605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine gluconate 2% topical cloths
Study NCT02282605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate 2% topical cloths
Study NCT04581694 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TAVI without contrast
Description: TAVI without contrast
Study NCT01852409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT05428657 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EC Brain After-school Program
Description: * Computerized Eye-tracking Attention and Impulse Control Training~* Computerized Temporal Processing Training~* Education on Relaxation, Stress Management and Healthy Balanced Diet
Study NCT05428657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional intervention
Description: Conventional cognitive training on their language and learning capacities (e.g., learning adjectives, logical reasoning, composition, reading words and story) and attention ability
Study NCT02461277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track protocol
Description: Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
Study NCT03770767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting Aspart insulin Fiasp
Description: Randomization to treatment with insulin Fiasp
Study NCT03770767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (insulin Novorapid)
Description: Randomization to standard treatment with insulin Novorapid
Study NCT04235751 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional Coaching
Description: 6 individualized professional coaching sessions via phone
Study NCT03766737 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: An intelligent visual acuity diagnostic system for children
Description: An artificial intelligence to make evaluation and of children's vision.
Study NCT03163303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Status Project Intervention
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use
Study NCT03163303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Status Project + Alcohol Intervention
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
Study NCT03163303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: 14-day supply of nicotine patch
Study NCT00808080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMLCTL
Description: Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
Study NCT04207762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F-AmBF3-TATE PET/CT
Description: Blood pressure, heart rate, and oxygen saturation levels and EKG monitoring (vital signs) will be recorded prior to the injection and at three other stages of the scan visit. Each study subject will have an intravenous catheter inserted. Prior to the radiotracer injection an ultra low dose CT will be taken. Subjects are positioned supine, arms down. The subject will receive a bolus intravenous dose of the radiotracer from an approved study supplier site. A Dynamic PET scan will be taken of the heart. Then a serial whole body PET scan will be done. Vital signs will be taken again and the subject will have a bathroom break. The patient will return to the scanner bed for a standard low dose CT and whole body PET scan. Vital signs will be taken again, and subject will be allowed to use the washroom again. The subject will return to the scanner bed for the final time for an ultra low dose CT and whole body PET scan. A final set of vitals will be taken and the subject will be discharged.
Study NCT04207762 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Routine blood draw
Description: Complete blood counts and routine clinical chemistry performed before and repeated within 18-72 hours after \[18F\]AmBF3-TATE administration.
Study NCT03746158 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: subjects will be assigned to consume one capsule of curcumin (330 mg of curcumin per capsule) three times a day (one capsule with each meal).
Study NCT02345993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extra fine Formoterol/Beclomethasone
Description: standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation~+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes
Study NCT01474252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSI
Description: All medications are administered only one dose before intubation~Anesthetics:~Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg~Neuromuscular blocking agents:~Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg~Opioid:~Fentanyl 1-2ug/kg
Study NCT04470076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment: Afatinib, pemetrexed, gemcitabine, cisplatin, carboplatin
Description: ① Eligible patients with non-squamous cell lung cancer will receive pemetrexed 500mg/m2, IV on day 1 and cisplatin 75mg/m2 or carboplatin area under curve (AUC) =5, on day 1 of a 3-week schedule for 3 cycles.~② Eligible patients with squamous cell lung cancer will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 or carboplatin AUC =5 on day 1 of a 3-week schedule for 3 cycles .~③Patient will take afatinib at dosage of 30mg per day 48 hours after chemotherapy and will stop 24 hours before next cycle of chemotherapy.
Study NCT04470076 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Description: The patients who respond to neoadjuvant treatment (CR+PR) and the patients who do not respond to therapy but could still undergo surgery (SD and PD) will receive radical lung resection 3-4 weeks later after neoadjuvant.
Study NCT04470076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant treatment:afatinib
Description: The CR, PR and SD patients who have been treated surgically will take afatinib at a dosage of 30mg per day for 2 year.
Study NCT04493788 — intervention group
Intervention type: OTHER
Intervention: Blood test, ultrasound and egg retrieval
Description: Blood tests will be performed to determine free testosterone levels, anti-mullerian hormone (AMH) and lipid profile including fasting plasma glucose and insulin. Women from both PCOS and control groups will be minimally stimulated with gonadotrophins and cumulus-oocytes complexes (COCs) will be aspirated from small antral follicles (2-8mm) without any ovulation triggering. Specifically, administration of highly purified human menopausal gonadotropin (HP-hMG) will start on cycle Day 3 of the menstrual period or a withdrawal bleeding. A pelvic ultrasound scan will be performed in the morning of the last stimulation day to schedule the oocyte collection. Cumulus-oocyte complexes retrieved 42 hours after the last gonadotropin injection will be collected, washed, denuded and individually stored for further molecular characterization.
Study NCT02724748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
Study NCT03378271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultanious CGM/FGM
Description: Patients will use both CGM and FGM and document their values as well as documenting a capillary blood glucose value.
Study NCT02404025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Eltrombopag was provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
Study NCT02404025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection was administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
Study NCT02404025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: CsA as capsules, oral solution, or fine granule, was administered at a dose of 3 mg per kg twice a day.